Kazia Therapeutics (KZIA) Current Deferred Revenue (2016 - 2018)

Kazia Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $104471.1 in Q2 2018.

• For the quarter ending Q2 2018, Current Deferred Revenue rose 239.2% year-over-year to $104471.1; the trailing twelve-month figure through Jun 2018 stood at $104471.1 (up 239.2% YoY), and the FY2018 full-year result was $104471.1, up 239.2% from the prior year.
• Current Deferred Revenue for Q2 2018 stood at $104471.1, up from $30799.6 in the prior quarter.
• The five-year high for Current Deferred Revenue was $137892.6 in Q4 2016, with the low at $30617.0 in Q2 2016.
• Historically, Current Deferred Revenue has averaged $75945.1 across 3 years, with a median of $67635.4 in 2017.
• Annual changes were most pronounced in 2017 — Current Deferred Revenue grew 0.6% — and 2018, when it soared 239.2%.
• Kazia Therapeutics' Current Deferred Revenue stood at $137892.6 in 2016, then plunged by 77.66% to $30799.6 in 2017, then soared by 239.2% to $104471.1 in 2018.
• The last three Current Deferred Revenue figures came in at $104471.1 (Q2 2018), $30799.6 (Q2 2017), and $137892.6 (Q4 2016), per Business Quant data.